Eli Lilly has agreed to splash out $8bn on smaller rival Loxo Oncology, the latest in a series of multibillion-dollar pharmaceutical deals as traditional drugmakers buttress cancer treatment portfolios with novel therapies that have been proven effective in treating the disease.
The deal comes ju
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
